fibromyalgia

Road closed and detour signs

Fierce Biotech

FDA refuses Axsome filing for former Pfizer fibromyalgia asset

Axsome is plotting another phase 3 trial to make up for a study that the FDA deemed inadequate and not well-controlled.

Darren Incorvaia Jun 9, 2025 12:27pm

signing contract

Sorrento moves to buy delayed burst release naltrexone drug

Mar 9, 2021 9:15am